Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Metilfenidato nei sopravvissuti al tumore cerebrale pediatrico con affaticamento correlato al cancro (EMBRAIN)

30 ottobre 2026 aggiornato da: Odense University Hospital

Effetto del metilfenidato sulla fatica correlata al cancro nei pazienti trattati per un tumore al cervello durante l'infanzia o l'adolescenza: protocollo per uno studio crossover randomizzato, in doppio cieco, controllato con placebo-lo studio ad abbraccio

Cancer-related fatigue is a common and debilitating late effect in pediatric brain tumor survivors. Currently, evidence-based recommendations to ameliorate this condition are lacking.

The researchers will investigate the ability of methylphenidate to improve fatigue and cognition in pediatric brain tumor survivors suffering from cancer-related fatigue. Methylphenidate is a drug (central nervous stimulant) most commonly used in the treatment of hyperkinetic disorders such as attention-deficit/hyperactivity disorder (ADHD).

If methylphenidate shows an effect, the prospects are important for this patient group, since methylphenidate may then be included as part of the treatment of brain tumor-related fatigue.

Panoramica dello studio

Tipo di studio

Interventistico

Iscrizione (Stimato)

50

Fase

  • Fase 3

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Contatto studio

Backup dei contatti dello studio

Luoghi di studio

      • Aalborg, Danimarca, 9000
        • Reclutamento
        • Aalborg University Hospital
        • Contatto:
          • Christina Friis Jensen, Consultant, MD
          • Numero di telefono: +45 97663368
          • Email: cfj@rn.dk
        • Investigatore principale:
          • Christina Friis Jensen, Consultant, MD
      • Aarhus, Danimarca, 8200
        • Reclutamento
        • Aarhus University Hospital
        • Contatto:
          • Louise T Henriksen, MD, PhD
          • Numero di telefono: +45 20921611
          • Email: louhen@rm.dk
        • Investigatore principale:
          • Louise T Henriksen, MD, PhD
      • Copenhagen, Danimarca, 2100
        • Reclutamento
        • Rigshospitalet
        • Contatto:
        • Investigatore principale:
          • Christine Dahl, Consultant, MD, PhD
      • Odense, Danimarca, 5000
        • Reclutamento
        • Odense University Hospital
        • Contatto:
        • Investigatore principale:
          • Sebastian W Most-Mottelson, MD, PhD Student

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

Da 6 anni a 27 anni (Bambino, Adulto)

Accetta volontari sani

No

Sessi ammissibili allo studio

Tutto

Descrizione

Inclusion Criteria:

  1. Diagnosed and treated for a brain tumor during childhood or adolescence (0-≤18 years).
  2. Treated for a brain tumor during the previous 10 years.
  3. Age ≥6 years and <28 years at the start of the trial.
  4. Off therapy/active treatment for pediatric brain tumor (PBT) for 12 months at the start of the trial.
  5. No known signs of clinical or radiological tumor progression at last follow-up.
  6. Danish is the sole or primary language (enabling provision of validated assessment tools).
  7. Patient and family have provided consent for inclusion in the trial.
  8. Clinically significant fatigue based on the PedsQL MFS questionnaire at baseline, defined by a score ≥ 1 standard deviation below the normative mean.
  9. History of clinically relevant fatigue after treatment of PBT compared to estimated premorbid ability, as assessed from consultations in the childhood cancer outpatient clinics.

Exclusion Criteria:

  1. Any known contraindications to methylphenidate as outlined below:

    A) Hypersensitivity to the active substance or any excipients listed in the summary of product characteristics. B) Glaucoma. C) Pheochromocytoma. D) Hyperthyroidism. E) Mania. F) Psychosis. G) Anorexia nervosa. H) Current or previous severe depression. I) Suicidal behavior. J) Poorly controlled type 1 bipolar affective disorder. K) Antisocial or borderline personality disorder. L) Pre-existing cardiovascular disorders, including severe hypertension, heart failure, arterial occlusive disease, angina pectoris, hemodynamically significant congenital heart disease, cardiomyopathies, myocardial infarction, potentially life-threatening cardiac arrhythmias and channelopathies. M) Pre-existing cerebrovascular disease, cerebral aneurysm, vascular abnormalities including vasculitis or stroke. N) Treatment with irreversible MAO inhibitors within the last 14 days and reversible MAO inhibitors within the last 24 hours.

  2. History of recent poorly controlled seizures.

  3. Complex tics or Tourette syndrome (including family history of tic disorder).

  4. Known diagnosis of Attention Deficit/Hyperactivity Disorder or Autism Spectrum Disorder.

  5. Known diagnosis of Full Scale Intelligence Quotient (FSIQ) of <50.

  6. Pregnancy. Participants known to be pregnant or breastfeeding at screening/registration will not be enrolled in the trial. All sexually active women of childbearing potential (WOCBP) must have a negative pregnancy test prior to the start of treatment. Acceptableeffective contraceptive must be used for the duration of the trial. No further testing is needed during trial, unless the participant suspects to have become pregnant.

  7. Concerns about family ability to safely store or administer MPH, or to report side effects appropriately/concerns about familial substance abuse.

  8. Concurrent use of opiods (ATC N02A) or benzodiazepines (ATC N05BA and N05CF).

  9. Simultaneously enrolled in another clinical trial investigating cancer-related fatigue with a pharmaceutical intervention.

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Trattamento
  • Assegnazione: Randomizzato
  • Modello interventistico: Assegnazione incrociata
  • Mascheramento: Quadruplicare

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Sperimentale: Methylphenidate, Then Placebo

Patients will receive treatment with methylphenidate tablets for 6 weeks, and then cross over to treatment with methylphenidate-matched placebo tablets for an additional 6 weeks. A four week wash out period is incorporated between treatments.

10 mg methylphenidate tablets with a scoreline. Tablets will be administered orally.

For children aged 6-12, a daily dose of 5 mg x 2 will be administered during the first week with an increase in dose to 10 mg x 2 in the second week. For adolescents and adults above 12 years of age, the same starting dose will be used as for children, with weekly incremental increases up to a maximum of 15 mg x 2 daily in the third week. In case of potential toxicity events during study, dosage of methylphenidate can be modified according to protocol.

10 mg methylphenidate-matched placebo tablets with a scoreline. Tablets will be administered orally.

Dosage will follow the exact same principles as for the study drug (methylphenidate).

Sperimentale: Placebo, Then Methylphenidate

Patients will receive treatment with methylphenidate-matched placebo tablets for 6 weeks, and then cross over to treatment with methylphenidate tablets for an additional 6 weeks. A four week wash out period is incorporated between treatments.

10 mg methylphenidate tablets with a scoreline. Tablets will be administered orally.

For children aged 6-12, a daily dose of 5 mg x 2 will be administered during the first week with an increase in dose to 10 mg x 2 in the second week. For adolescents and adults above 12 years of age, the same starting dose will be used as for children, with weekly incremental increases up to a maximum of 15 mg x 2 daily in the third week. In case of potential toxicity events during study, dosage of methylphenidate can be modified according to protocol.

10 mg methylphenidate-matched placebo tablets with a scoreline. Tablets will be administered orally.

Dosage will follow the exact same principles as for the study drug (methylphenidate).

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
PedsQL Multidimensional Fatigue Scale (MFS)
Lasso di tempo: At baseline, at Week 6, Week 16, and Week 20 (follow-up).

Changes in patient self-reported fatigue (participants above 18 years of age) or parent proxy-reported fatigue (participants between 6-17 years of age) from baseline to week 6 of MPH or placebo treatment as measured by the PedsQL Multidimensional Fatigue Scale (MFS).

At baseline, at Week 6, Week 16, and Week 20 (follow-up).

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
PedsQL Multidimensional Fatigue Scale (MFS)
Lasso di tempo: At baseline, at Week 6, Week 16, and Week 20 (follow-up).

Changes from baseline in self-reported fatigue (participants aged 6-17 years of age) measured by the PedsQL MFS.

At baseline, at Week 6, Week 16, and Week 20 (follow-up).
Behaviour Rating Inventory of Executive Function (BRIEF)
Lasso di tempo: At baseline, at Week 6, and Week 16.

Changes from baseline in self and parent-reported executive function measured by the BRIEF-2 or BRIEF-V questionnaire.

At baseline, at Week 6, and Week 16.
Connor's Continuous Performance Test (CPT) Online Suite
Lasso di tempo: At baseline, at Week 6, and Week 16.

Changes from baseline in digital measures of sustained attention and executive function. CPT-3 and K-CPT-2 will be used.

At baseline, at Week 6, and Week 16.
Wechsler Coding
Lasso di tempo: At baseline, at Week 6, and Week 16.

Changes from baseline in processing speed. Coding module from Wechsler Intelligence Scale for Children Fifth Edition (WISC-V) or Wechsler Adult Intelligence Scale Fifth Edition (WAIS-V) depending on age of participant.

At baseline, at Week 6, and Week 16.
Wechsler Digit Span
Lasso di tempo: At baseline, at Week 6, and Week 16.

Changes from baseline in working memory. Coding module from WISC-V or WAIS-V depending on age of participant.

At baseline, at Week 6, and Week 16.
PedsQL Generic Core Scales
Lasso di tempo: At baseline, at Week 6, and Week 16.

Changes from baseline in self and parent-reported measures of Health Related Quality of Life.

At baseline, at Week 6, and Week 16.
Accelerometry (Axivity AX3)
Lasso di tempo: Accelerometry will be performed for a duration of 1 week during week 4-6 and week 14-16 during the study arm.

Time spent within different activity domains and sleep-wake patterns measured by accelerometry. Axivity AX3 accelerometers will be used.

Accelerometry will be performed for a duration of 1 week during week 4-6 and week 14-16 during the study arm.
Barkley's Stimulant Side Effect Rating Scale (SSERS)
Lasso di tempo: At baseline, Week 2, Week 3, Week 4, Week 6, Week 10, Week 12, Week 13, Week 14, Week 16, and Week 20 (follow-up)..

Changes from baseline in self and parent-reported side-effects. A modified version of SSERS with 21 items customized to Danish practice will be used.

At baseline, Week 2, Week 3, Week 4, Week 6, Week 10, Week 12, Week 13, Week 14, Week 16, and Week 20 (follow-up)..

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Investigatori

  • Direttore dello studio: Mathias Rathe, Consultant, MD, PhD, Odense University Hospital

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

2 settembre 2025

Completamento primario (Stimato)

1 dicembre 2029

Completamento dello studio (Stimato)

1 dicembre 2029

Date di iscrizione allo studio

Primo inviato

27 novembre 2024

Primo inviato che soddisfa i criteri di controllo qualità

25 marzo 2025

Primo Inserito (Effettivo)

1 aprile 2025

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

3 novembre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

30 ottobre 2026

Ultimo verificato

1 ottobre 2026

Maggiori informazioni

Termini relativi a questo studio

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

NO

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

No

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

prodotto fabbricato ed esportato dagli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .

Sottoscrivi